Join

Compare · NVO vs OGEN

NVO vs OGEN

Side-by-side comparison of Novo Nordisk A/S (NVO) and Oragenics Inc. (OGEN): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both NVO and OGEN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NVO is the larger of the two at $191.82B, about 71570.6x OGEN ($2.7M).
  • Over the past year, NVO is down 45.7% and OGEN is down 86.5% - NVO leads by 40.9 points.
  • NVO has been more active in the news (8 items in the past 4 weeks vs 5 for OGEN).
  • NVO has more recent analyst coverage (25 ratings vs 0 for OGEN).
PerformanceNVO-48.32%OGEN-86.52%
2025-06-10+0.00%2026-06-08
MetricNVOOGEN
Company
Novo Nordisk A/S
Oragenics Inc.
Price
$41.01-4.51%
$0.59+0.68%
Market cap
$191.82B
$2.7M
1M return
-10.44%
-4.21%
1Y return
-45.66%
-86.52%
Sector
Health Care
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NYSE
AMEX
IPO
News (4w)
8
5
Recent ratings
25
0
NVO

Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

OGEN

Oragenics Inc.

Oragenics, Inc. develops antibiotics for infectious diseases in the United States. Its lead product candidate under development is OG716, an antibiotic for the treatment of Clostridium difficile. The company also engages in the development and commercialization of Terra CoV-2, a vaccine product candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. Its product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. The company has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and production of lantibiotics, a peptide antibiotic that are naturally produced in gram-positive bacteria. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

Latest NVO

Latest OGEN